You are here

SBIR TOPIC 431 - MOBILE ORAL-CANCER SCREENING AND TREATMENT (MOST) SYSTEM FOR LOW-RESOURCE SETTINGS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N91022C00019
Agency Tracking Number: 75N91022C00019
Amount: $399,862.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 431
Solicitation Number: PHS-2022-1
Timeline
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4815 N ROCK CANYON RD
TUCSON, AZ 85750-6064
United States
DUNS: 080295846
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RONGGUANG LIANG
 (520) 906-8788
 lightresearchinc@gmail.com
Business Contact
 RONGGUANG LIANG
Phone: (520) 906-8788
Email: lightresearchinc@gmail.com
Research Institution
N/A
Abstract

Oral and oropharyngeal squamous cell carcinoma (OSCC) together rank as the sixth most common cancer worldwide, it is the most common cancer in some low- and middle- income countries (LMICs). The poor survival rate in LMICs and rural regions in developed countries is mainly due to late diagnosis and the resultant progression of disease to an advanced stage at diagnosis. Motivated by the successes in the two different NIH UH2/UH3 projects for detecting and treating pre- and early oral cancers, Light Research Inc (LRI) proposes to develop and commercialize a new integrated mobile oral-cancer screening and treatment (MOST) system, optimized for low-resource settings (LRS). It combines dual-modal oral cancer screening technology and photochemistry-based, FDA approved photodynamic therapy (PDT) modality. We will first develop the MOST system (Aim 1) and then demonstrate the imaging and treatment performance of MOST system with murine subcutaneous xenograft model (Aim 2). This project is significant because early diagnosis of oral cancers and timely treatment can reduce disease progression, reduce morbidity and mortality, and cut costs. It addresses the major barrier to screen high-risk population and treat patients with high risk oral premalignant and malignant lesions (OPML) and early-stage oral cancer in LRS.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government